Treatment progress of peripheral T-cell lymphoma: reports from the 56th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2015.01.006
- VernacularTitle:外周T细胞淋巴瘤治疗进展:第56届美国血液学会年会报道
- Author:
Jinbo LU
;
Lei FAN
;
Wei XU
;
Jianyong LI
- Publication Type:Journal Article
- Keywords:
Peripheral T-cell lymphoma;
Treatment;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2015;24(1):17-19,26
- CountryChina
- Language:Chinese
-
Abstract:
Peripheral T-cell lymphoma (PTCL) is a group of highly heterogeneous and aggressive non-Hodgkin's lymphoma with poor prognosis under current treatment algorithm.Reports on treatment of PTCL in the 56th American Society of Hematology (ASH) annual meeting cover comprehensive aspects,among which exploration of effective low-toxicity treatment strategies for patients with PTCL is coming into the focus of this meeting.THP-COP regimen,romidepsin,bortezomib alone or in combination with panobinostat,brentuximab vedotin and stem cell transplantation provide more attractive options for both untreated and refractory/relapsed patients with PTCL,while novel drugs including Duvelisib (IPI-145),crizotinib and antiPD-1 antibody offer new hope for patients with PTCL.
